Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis (BE ABLE 1)

14 lipca 2022 zaktualizowane przez: UCB Biopharma S.P.R.L.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to investigate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of Bimekizumab compared with placebo in adult subjects with moderate to severe chronic plaque psoriasis in order to guide the selection of doses and clinical indices in the Phase 3 development program.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

250

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Czechy
      • Ostrava Poruba, Czechy
        • Ps0010 300
      • Pardubice, Czechy
        • Ps0010 303
      • Praha, Czechy
        • Ps0010 301
      • Praha, Czechy
        • Ps0010 304
  • Japonia
      • Nagoya, Japonia
        • Ps0010 502
      • Shinaga Wa-ku, Japonia
        • Ps0010 501
      • Tokio, Japonia
        • Ps0010 503
      • Tokyo, Japonia
        • Ps0010 504
  • Kanada
      • Edmonton, Kanada
        • Ps0010 209
      • Quebec City, Kanada
        • Ps0010 214
    • British Columbia
      • Surrey, British Columbia, Kanada
        • Ps0010 203
    • Ontario
      • Hamilton, Ontario, Kanada
        • Ps0010 204
      • North Bay, Ontario, Kanada
        • Ps0010 201
      • Peterborough, Ontario, Kanada
        • Ps0010 206
      • Waterloo, Ontario, Kanada
        • Ps0010 205
    • Quebec
      • Quebec City, Quebec, Kanada
        • Ps0010 214
  • Polska
      • Bialystok, Polska
        • Ps0010 600
      • Bialystok, Polska
        • Ps0010 611
      • Gdansk, Polska
        • Ps0010 605
      • Gdynia, Polska
        • Ps0010 610
      • Kielce, Polska
        • Ps0010 604
      • Krakow, Polska
        • Ps0010 608
      • Lublin, Polska
        • Ps0010 606
      • Podlaski, Polska
        • Ps0010 603
      • Warszawa, Polska
        • Ps0010 607
      • Wroclaw, Polska
        • Ps0010 601
      • Wroclaw, Polska
        • Ps0010 609
  • Stany Zjednoczone
    • California
      • Fremont, California, Stany Zjednoczone
        • Ps0010 711
      • Los Angeles, California, Stany Zjednoczone
        • Ps0010 708
    • District of Columbia
      • Washington, District of Columbia, Stany Zjednoczone
        • Ps0010 706
    • Iowa
      • West Des Moines, Iowa, Stany Zjednoczone
        • Ps0010 704
    • New York
      • Rochester, New York, Stany Zjednoczone
        • Ps0010 718
    • North Carolina
      • Wilmington, North Carolina, Stany Zjednoczone
        • Ps0010 738
    • Ohio
      • Cleveland, Ohio, Stany Zjednoczone
        • Ps0010 736
    • Oregon
      • Portland, Oregon, Stany Zjednoczone
        • Ps0010 712
    • Texas
      • Dallas, Texas, Stany Zjednoczone
        • Ps0010 733
      • Houston, Texas, Stany Zjednoczone
        • Ps0010 702
      • Houston, Texas, Stany Zjednoczone
        • Ps0010 709
  • Węgry
      • Kecskemet, Węgry
        • Ps0010 404
      • Oroshaza, Węgry
        • Ps0010 400
      • Szekszard, Węgry
        • Ps0010 405

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Subject has provided informed consent
  • Chronic plaque psoriasis for at least 6 months prior to Screening
  • PASI (Psoriasis Area and Severity Index) >=12 and BSA (body surface area) >=10% and IGA (Investigator's Global Assessment) score 3 or greater on a 5-point scale
  • Candidates for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy
  • Female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception up till 20 weeks after last administration of study drug
  • Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active, up till 20 weeks after the last administration of study medication

Exclusion Criteria:

  • Subjects with erythrodermic, guttate, pustular form of psoriasis, or drug-induced psoriasis
  • Subject has any severe, progressive and/or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, gastrointestinal or neurological disease
  • Subject has any significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol
  • Subject taking prohibited psoriatic medications
  • Subject receiving any live vaccines within 8 weeks prior to the Baseline and subjects receiving Bacillus Calmette-Guerin (BCG) vaccination within 1 year prior to study drug administration
  • Subject has previously received treatment with any anti-interleukin-17 (anti-IL-17) therapy or has been exposed to more than 1 biological response modifier (limited to anti-tumor necrosis factor (TNF) or IL-12/23) for psoriatic arthritis or psoriasis prior to the Baseline
  • Subject has any current sign or symptom that may indicate an active infection (except for common cold)

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Komparator placebo: Placebo
Inny: Placebo
Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
Eksperymentalny: Bimekizumab dosing regimen 1
Inny: Placebo
Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
Lek: Bimekizumab
Subjects will be randomized to receive a combination of injections of Bimekizumab.
Inne nazwy:
  • UCB4940
Eksperymentalny: Bimekizumab dosing regimen 2
Inny: Placebo
Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
Lek: Bimekizumab
Subjects will be randomized to receive a combination of injections of Bimekizumab.
Inne nazwy:
  • UCB4940
Eksperymentalny: Bimekizumab dosing regimen 3
Inny: Placebo
Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
Lek: Bimekizumab
Subjects will be randomized to receive a combination of injections of Bimekizumab.
Inne nazwy:
  • UCB4940
Eksperymentalny: Bimekizumab dosing regimen 4
Inny: Placebo
Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
Lek: Bimekizumab
Subjects will be randomized to receive a combination of injections of Bimekizumab.
Inne nazwy:
  • UCB4940
Eksperymentalny: Bimekizumab dosing regimen 5
Lek: Bimekizumab
Subjects will be randomized to receive a combination of injections of Bimekizumab.
Inne nazwy:
  • UCB4940

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12
Ramy czasowe: Week 12
The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
Week 12

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants With Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least 2 Category Improvement From Baseline) Response at Week 12
Ramy czasowe: Week 12
The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.
Week 12
Percentage of Participants With Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least 2 Category Improvement From Baseline) Response at Week 8
Ramy czasowe: Week 8
The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.
Week 8
Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 8
Ramy czasowe: Week 8
The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
Week 8
Percentage of Participants Achieving a 75% or Higher Improvement in Psoriasis Area and Severity Index (PASI) Score at Week 12
Ramy czasowe: Week 12
The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
Week 12
Percentage of Participants Achieving a 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12
Ramy czasowe: Week 12
PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72. The PASI 100 response rate at Week 12 is measured as the percentage of participants who achieved 100% improvement from baseline PASI at Week 12.
Week 12
Plasma Concentrations of Bimekizumab During the Study
Ramy czasowe: Baseline (Week 0), Week 1, Week 2, Week 4, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

Bimekizumab plasma concentration was expressed in micrograms per milliliter (μg/mL).

Values Below Limit of Quantification (BLQ) were replaced by the value of lower limit of quantification (LLOQ) divided by 2 = 0.075 μg/mL in the calculations of geometric mean and confidence intervals (CIs). Geometric mean was only calculated if at least two-thirds of the concentrations were quantified at the respective time point.
Baseline (Week 0), Week 1, Week 2, Week 4, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Population PK (Apparent Total Clearance (CL/F)) of Bimekizumab
Ramy czasowe: From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)

The data were presented as population estimates of CL/F. Given the sparse nature of PK sampling, CL/F cannot be estimated for each treatment group.

It was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.
From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)
Population PK (Apparent Volume of Distribution (V/F)) of Bimekizumab
Ramy czasowe: From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)

The data were presented as population estimates of V/F. Given the sparse nature of PK sampling, V/F cannot be estimated for each treatment group.

It was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.
From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)
Concentration of Bimekizumab Leading to 50% of Maximum Effect (EC50)
Ramy czasowe: From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)

The data were presented as population estimates of EC50. EC50 was estimated based on all available data and cannot be derived for each treatment arm.

It was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.
From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)
Percentage of Participants With a Positive Anti-bimekizumab Antibody (AbAb) Status Prior to Study Treatment
Ramy czasowe: Baseline (Week 0)
Antibody positive status prior study treatment was defined as having an antibody level greater than (>) 28.5% at Baseline (Week 0).
Baseline (Week 0)
Percentage of Participants With an Overall Positive Anti-bimekizumab Antibody (AbAb) Status Following Study Treatment
Ramy czasowe: From Week 4 until the Safety Follow-Up visit (20 weeks after the last dose; Up to Week 28)
Overall antibody positive was defined as having a value of > 28.5% at any time in the Treatment Period. The Treatment Period did not include Baseline/pretreatment samples.
From Week 4 until the Safety Follow-Up visit (20 weeks after the last dose; Up to Week 28)
Percentage of Participants With at Least One Adverse Event (AE) During the Study
Ramy czasowe: From Screening to End of Safety Follow-up (up to Week 32)
An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.
From Screening to End of Safety Follow-up (up to Week 32)
Percentage of Participants With at Least One Adverse Event (AE) During the Study by Severity
Ramy czasowe: From Screening to End of Safety Follow-up (up to Week 32)
An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.
From Screening to End of Safety Follow-up (up to Week 32)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Platelets)
Ramy czasowe: Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Platelets was measured in number of platelets per liter (10^9/L).
Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin)
Ramy czasowe: Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Erythrocytes mean corpuscular hemoglobin (HGB) concentration and hemoglobin were measured in grams per liter (g/L).
Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB))
Ramy czasowe: Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Erythrocytes mean corpuscular hemoglobin (HGB) was measured in picograms (pg).
Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Volume)
Ramy czasowe: Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Erythrocytes mean corpuscular volume was measured in femtolitres (fL).
Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes)
Ramy czasowe: Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Erythrocytes was measured in number of red blood cells per liter (10^12/L).
Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Hematocrit)
Ramy czasowe: Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Hematocrit was measured in volume percentage (%) of red blood cells in blood.
Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils)
Ramy czasowe: Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Basophils, eosinophils, leukocytes, lymphocytes, monocytes and neutrophils were measured in number of white blood cells per liter (10^9/L).
Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Calcium, Chloride, Potassium, Magnesium, Sodium, Urea Nitrogen, Cholesterol, Glucose)
Ramy czasowe: Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Calcium, chloride, potassium, magnesium, sodium, urea nitrogen, cholesterol and glucose were measured in millimoles per liter (mmol/L).
Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Lactate Dehydrogenase, Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase)
Ramy czasowe: Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Lactate dehydrogenase, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase and gamma glutamyl transferase were measured in units per liter (U/L).
Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Creatinine, Bilirubin)
Ramy czasowe: Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Creatinine and bilirubin were measured in micromols per liter (μmol/L).
Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (C Reactive Protein)
Ramy czasowe: Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
C Reactive Protein was measured in milligrams per liters (mg/L).
Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Change From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (pH)
Ramy czasowe: Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Urine pH was measured on a pH scale.
Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Leukocyte Esterase)
Ramy czasowe: From Baseline (Week 0) until Week 12
Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.
From Baseline (Week 0) until Week 12
Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Nitrite)
Ramy czasowe: From Baseline (Week 0) until Week 12
Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.
From Baseline (Week 0) until Week 12
Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Occult Blood)
Ramy czasowe: From Baseline (Week 0) until Week 12
Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.
From Baseline (Week 0) until Week 12
Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Urine Glucose)
Ramy czasowe: From Baseline (Week 0) until Week 12
Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.
From Baseline (Week 0) until Week 12
Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Albumin)
Ramy czasowe: From Baseline (Week 0) until Week 12
Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.
From Baseline (Week 0) until Week 12
Change From Baseline Until Safety Follow-up Visit in Vital Signs (Blood Pressure)
Ramy czasowe: Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Blood pressure was measured in millimeters of mercury (mmHg).
Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Change From Baseline Until Safety Follow-up Visit in Vital Signs (Pulse Rate)
Ramy czasowe: Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Pulse rate was measured in beats per minute (beats/min).
Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Change From Baseline Until Safety Follow-up Visit in Vital Signs (Temperature)
Ramy czasowe: Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Temperature was measured in degrees Celsius (°C).
Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Percentage of Participants With Clinically Significant Physical Examination Abnormalities
Ramy czasowe: At Screening, Week 12/Early Withdrawal Visit and the Safety Follow-Up Visit (20 weeks after the last dose)

The physical examination included general appearance; ear, nose, and throat; eyes, hair, and skin; respiratory; CV; GI; musculoskeletal; hepatic; neurological (including limb reflexes); and mental status.

Any clinically significant abnormal findings during the study were captured as adverse events.
At Screening, Week 12/Early Withdrawal Visit and the Safety Follow-Up Visit (20 weeks after the last dose)
Percentage of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings
Ramy czasowe: Baseline (Week 0), Week 2, Week 4, Week 6, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)
Percentages were based on the number of participants with a non-missing measurement for that variable at the visit.
Baseline (Week 0), Week 2, Week 4, Week 6, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

UCB Biopharma S.P.R.L.

Współpracownicy

Parexel

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 sierpnia 2016

Zakończenie podstawowe (Rzeczywisty)

1 czerwca 2017

Ukończenie studiów (Rzeczywisty)

1 lipca 2017

Daty rejestracji na studia

Pierwszy przesłany

14 września 2016

Pierwszy przesłany, który spełnia kryteria kontroli jakości

16 września 2016

Pierwszy wysłany (Oszacować)

19 września 2016

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

21 lipca 2022

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

14 lipca 2022

Ostatnia weryfikacja

1 lipca 2022

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • PS0010
  • 2016-001891-31 (Numer EudraCT)

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj